Intrinsic value of Amarin ADR - AMRN

Previous Close

$3.03

  Intrinsic Value

$0.69

stock screener

  Rating & Target

str. sell

-77%

  Value-price divergence*

0%

Previous close

$3.03

 
Intrinsic value

$0.69

 
Up/down potential

-77%

 
Rating

str. sell

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of AMRN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  58.54
  34.60
  31.64
  28.98
  26.58
  24.42
  22.48
  20.73
  19.16
  17.74
  16.47
  15.32
  14.29
  13.36
  12.52
  11.77
  11.09
  10.48
  9.94
  9.44
  9.00
  8.60
  8.24
  7.91
  7.62
  7.36
  7.12
  6.91
  6.72
  6.55
  6.39
Revenue, $m
  130
  175
  230
  297
  376
  468
  573
  692
  824
  971
  1,131
  1,304
  1,490
  1,689
  1,901
  2,124
  2,360
  2,607
  2,867
  3,137
  3,420
  3,714
  4,019
  4,338
  4,668
  5,012
  5,369
  5,740
  6,126
  6,527
  6,945
Variable operating expenses, $m
 
  77
  101
  130
  165
  205
  251
  303
  361
  425
  495
  571
  653
  740
  832
  930
  1,034
  1,142
  1,256
  1,374
  1,498
  1,627
  1,761
  1,900
  2,045
  2,195
  2,352
  2,514
  2,683
  2,859
  3,042
Fixed operating expenses, $m
 
  151
  154
  158
  162
  166
  170
  175
  179
  184
  188
  193
  198
  203
  208
  213
  218
  224
  229
  235
  241
  247
  253
  259
  266
  273
  279
  286
  293
  301
  308
Total operating expenses, $m
  196
  228
  255
  288
  327
  371
  421
  478
  540
  609
  683
  764
  851
  943
  1,040
  1,143
  1,252
  1,366
  1,485
  1,609
  1,739
  1,874
  2,014
  2,159
  2,311
  2,468
  2,631
  2,800
  2,976
  3,160
  3,350
Operating income, $m
  -66
  -52
  -25
  9
  49
  97
  152
  214
  284
  362
  447
  540
  640
  747
  860
  981
  1,108
  1,242
  1,382
  1,528
  1,681
  1,840
  2,006
  2,178
  2,358
  2,544
  2,738
  2,940
  3,149
  3,367
  3,594
EBITDA, $m
  -65
  -51
  -23
  11
  52
  100
  156
  219
  290
  369
  455
  549
  650
  758
  874
  996
  1,124
  1,260
  1,401
  1,550
  1,704
  1,866
  2,034
  2,208
  2,390
  2,579
  2,775
  2,979
  3,192
  3,412
  3,642
Interest expense (income), $m
  17
  11
  13
  19
  26
  35
  45
  56
  69
  83
  99
  116
  135
  155
  176
  199
  223
  248
  275
  303
  332
  362
  394
  427
  461
  497
  534
  572
  612
  653
  697
Earnings before tax, $m
  -76
  -63
  -38
  -11
  23
  62
  107
  158
  215
  279
  348
  424
  505
  592
  684
  782
  885
  993
  1,107
  1,225
  1,349
  1,478
  1,612
  1,752
  1,897
  2,048
  2,204
  2,368
  2,537
  2,714
  2,898
Tax expense, $m
  10
  0
  0
  0
  6
  17
  29
  43
  58
  75
  94
  114
  136
  160
  185
  211
  239
  268
  299
  331
  364
  399
  435
  473
  512
  553
  595
  639
  685
  733
  782
Net income, $m
  -86
  -63
  -38
  -11
  17
  45
  78
  115
  157
  204
  254
  309
  369
  432
  500
  571
  646
  725
  808
  894
  985
  1,079
  1,177
  1,279
  1,385
  1,495
  1,609
  1,728
  1,852
  1,981
  2,115

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  98
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  167
  225
  296
  382
  483
  601
  737
  889
  1,060
  1,248
  1,453
  1,676
  1,915
  2,171
  2,443
  2,730
  3,033
  3,351
  3,684
  4,032
  4,395
  4,773
  5,166
  5,575
  6,000
  6,442
  6,901
  7,378
  7,874
  8,390
  8,926
Adjusted assets (=assets-cash), $m
  69
  225
  296
  382
  483
  601
  737
  889
  1,060
  1,248
  1,453
  1,676
  1,915
  2,171
  2,443
  2,730
  3,033
  3,351
  3,684
  4,032
  4,395
  4,773
  5,166
  5,575
  6,000
  6,442
  6,901
  7,378
  7,874
  8,390
  8,926
Revenue / Adjusted assets
  1.884
  0.778
  0.777
  0.777
  0.778
  0.779
  0.777
  0.778
  0.777
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
  0.778
Average production assets, $m
  9
  12
  16
  20
  26
  32
  40
  48
  57
  67
  78
  90
  103
  117
  131
  147
  163
  180
  198
  216
  236
  256
  277
  299
  322
  346
  370
  396
  423
  450
  479
Working capital, $m
  70
  4
  5
  7
  9
  11
  13
  16
  19
  22
  26
  30
  34
  39
  44
  49
  54
  60
  66
  72
  79
  85
  92
  100
  107
  115
  123
  132
  141
  150
  160
Total debt, $m
  116
  142
  206
  284
  375
  481
  603
  740
  894
  1,063
  1,248
  1,448
  1,664
  1,894
  2,139
  2,397
  2,670
  2,956
  3,256
  3,569
  3,896
  4,236
  4,590
  4,958
  5,340
  5,738
  6,151
  6,580
  7,027
  7,491
  7,974
Total liabilities, $m
  176
  202
  266
  344
  435
  541
  663
  800
  954
  1,123
  1,308
  1,508
  1,724
  1,954
  2,199
  2,457
  2,730
  3,016
  3,316
  3,629
  3,956
  4,296
  4,650
  5,018
  5,400
  5,798
  6,211
  6,640
  7,087
  7,551
  8,034
Total equity, $m
  -9
  22
  30
  38
  48
  60
  74
  89
  106
  125
  145
  168
  192
  217
  244
  273
  303
  335
  368
  403
  440
  477
  517
  558
  600
  644
  690
  738
  787
  839
  893
Total liabilities and equity, $m
  167
  224
  296
  382
  483
  601
  737
  889
  1,060
  1,248
  1,453
  1,676
  1,916
  2,171
  2,443
  2,730
  3,033
  3,351
  3,684
  4,032
  4,396
  4,773
  5,167
  5,576
  6,000
  6,442
  6,901
  7,378
  7,874
  8,390
  8,927
Debt-to-equity ratio
  -12.889
  6.330
  6.970
  7.430
  7.760
  8.000
  8.190
  8.330
  8.430
  8.520
  8.590
  8.640
  8.690
  8.720
  8.750
  8.780
  8.800
  8.820
  8.840
  8.850
  8.860
  8.870
  8.880
  8.890
  8.900
  8.910
  8.910
  8.920
  8.920
  8.930
  8.930
Adjusted equity ratio
  -1.551
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -86
  -63
  -38
  -11
  17
  45
  78
  115
  157
  204
  254
  309
  369
  432
  500
  571
  646
  725
  808
  894
  985
  1,079
  1,177
  1,279
  1,385
  1,495
  1,609
  1,728
  1,852
  1,981
  2,115
Depreciation, amort., depletion, $m
  1
  1
  2
  2
  3
  3
  4
  5
  6
  7
  8
  9
  10
  12
  13
  15
  16
  18
  20
  22
  24
  26
  28
  30
  32
  35
  37
  40
  42
  45
  48
Funds from operations, $m
  -80
  -62
  -37
  -8
  19
  48
  82
  120
  163
  210
  262
  318
  379
  444
  513
  586
  662
  743
  828
  916
  1,008
  1,104
  1,204
  1,309
  1,417
  1,529
  1,646
  1,768
  1,895
  2,026
  2,163
Change in working capital, $m
  -8
  1
  1
  2
  2
  2
  2
  3
  3
  3
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  9
  10
Cash from operations, $m
  -72
  -63
  -38
  -10
  17
  46
  80
  117
  160
  207
  258
  314
  375
  439
  508
  580
  657
  737
  822
  910
  1,002
  1,098
  1,197
  1,301
  1,409
  1,521
  1,638
  1,759
  1,886
  2,017
  2,154
Maintenance CAPEX, $m
  0
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -12
  -13
  -15
  -16
  -18
  -20
  -22
  -24
  -26
  -28
  -30
  -32
  -35
  -37
  -40
  -42
  -45
New CAPEX, $m
  0
  -3
  -4
  -5
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -15
  -16
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
Cash from investing activities, $m
  0
  -4
  -5
  -7
  -7
  -9
  -10
  -12
  -14
  -16
  -18
  -20
  -22
  -24
  -27
  -28
  -31
  -33
  -36
  -39
  -41
  -44
  -47
  -50
  -53
  -56
  -60
  -63
  -67
  -70
  -74
Free cash flow, $m
  -72
  -67
  -43
  -16
  10
  37
  69
  105
  146
  191
  241
  295
  353
  415
  482
  552
  626
  704
  786
  871
  961
  1,054
  1,151
  1,252
  1,356
  1,465
  1,579
  1,697
  1,819
  1,947
  2,080
Issuance/(repayment) of debt, $m
  -1
  26
  64
  77
  91
  106
  122
  137
  153
  169
  185
  200
  215
  230
  245
  259
  273
  286
  300
  313
  327
  340
  354
  368
  383
  398
  413
  429
  446
  464
  483
Issuance/(repurchase) of shares, $m
  65
  95
  45
  19
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  63
  121
  109
  96
  91
  106
  122
  137
  153
  169
  185
  200
  215
  230
  245
  259
  273
  286
  300
  313
  327
  340
  354
  368
  383
  398
  413
  429
  446
  464
  483
Total cash flow (excl. dividends), $m
  -9
  54
  66
  80
  101
  144
  191
  243
  299
  360
  426
  495
  568
  645
  726
  811
  899
  990
  1,086
  1,185
  1,287
  1,394
  1,505
  1,620
  1,739
  1,863
  1,992
  2,126
  2,266
  2,411
  2,563
Retained Cash Flow (-), $m
  -119
  -95
  -45
  -19
  -10
  -12
  -14
  -15
  -17
  -19
  -21
  -22
  -24
  -26
  -27
  -29
  -30
  -32
  -33
  -35
  -36
  -38
  -39
  -41
  -43
  -44
  -46
  -48
  -50
  -52
  -54
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -41
  21
  61
  91
  132
  177
  227
  282
  341
  405
  473
  544
  620
  699
  782
  868
  959
  1,052
  1,150
  1,251
  1,356
  1,465
  1,579
  1,696
  1,819
  1,946
  2,078
  2,216
  2,360
  2,509
Discount rate, %
 
  7.00
  7.35
  7.72
  8.10
  8.51
  8.93
  9.38
  9.85
  10.34
  10.86
  11.40
  11.97
  12.57
  13.20
  13.86
  14.55
  15.28
  16.04
  16.85
  17.69
  18.57
  19.50
  20.48
  21.50
  22.58
  23.70
  24.89
  26.13
  27.44
  28.81
PV of cash for distribution, $m
 
  -38
  18
  49
  67
  88
  106
  121
  133
  141
  144
  144
  140
  133
  123
  112
  99
  85
  72
  60
  48
  38
  29
  22
  16
  11
  8
  5
  3
  2
  1
Current shareholders' claim on cash, %
  100
  50.0
  16.6
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1
  10.1

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product includes Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

FINANCIAL RATIOS  of  Amarin ADR (AMRN)

Valuation Ratios
P/E Ratio -9.5
Price to Sales 6.3
Price to Book -90.7
Price to Tangible Book
Price to Cash Flow -11.3
Price to Free Cash Flow -11.3
Growth Rates
Sales Growth Rate 58.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 3
Current Ratio 0
LT Debt to Equity -944.4%
Total Debt to Equity -1288.9%
Interest Coverage -3
Management Effectiveness
Return On Assets -39.3%
Ret/ On Assets - 3 Yr. Avg. -40.3%
Return On Total Capital -74.8%
Ret/ On T. Cap. - 3 Yr. Avg. -63.4%
Return On Equity 125.5%
Return On Equity - 3 Yr. Avg. 107.9%
Asset Turnover 0.8
Profitability Ratios
Gross Margin 73.8%
Gross Margin - 3 Yr. Avg. 67.6%
EBITDA Margin -44.6%
EBITDA Margin - 3 Yr. Avg. -86.8%
Operating Margin -50.8%
Oper. Margin - 3 Yr. Avg. -92.2%
Pre-Tax Margin -58.5%
Pre-Tax Margin - 3 Yr. Avg. -103.9%
Net Profit Margin -66.2%
Net Profit Margin - 3 Yr. Avg. -103.4%
Effective Tax Rate -13.2%
Eff/ Tax Rate - 3 Yr. Avg. -1.8%
Payout Ratio 0%

AMRN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AMRN stock intrinsic value calculation we used $130 million for the last fiscal year's total revenue generated by Amarin ADR. The default revenue input number comes from 2016 income statement of Amarin ADR. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AMRN stock valuation model: a) initial revenue growth rate of 34.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7%, whose default value for AMRN is calculated based on our internal credit rating of Amarin ADR, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Amarin ADR.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AMRN stock the variable cost ratio is equal to 43.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $147 million in the base year in the intrinsic value calculation for AMRN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.3% for Amarin ADR.

Corporate tax rate of 27% is the nominal tax rate for Amarin ADR. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AMRN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AMRN are equal to 6.9%.

Life of production assets of 10 years is the average useful life of capital assets used in Amarin ADR operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AMRN is equal to 2.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-9 million for Amarin ADR - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 267.59 million for Amarin ADR is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Amarin ADR at the current share price and the inputted number of shares is $0.8 billion.

RELATED COMPANIES Price Int.Val. Rating
TEVA Teva Pharmaceu 17.49 70.59  str.buy
ABBV AbbVie 70.42 70.36  hold
AZN AstraZeneca AD 29.18 17.48  sell
GSK GlaxoSmithKlin 39.24 96.05  str.buy
IONS Ionis Pharmace 47.41 495.91  str.buy

COMPANY NEWS

▶ Amarin reports 2Q loss   [Aug-02-17 10:55PM  Associated Press]
▶ ETFs with exposure to Amarin Corp. Plc : June 27, 2017   [Jun-27-17 02:51PM  Capital Cube]
▶ Opening Bell, June 13, 2017   [Jun-13-17 09:29AM  CNBC Videos]
▶ Today's Bell Ringer, June 13, 2017   [09:15AM  CNBC Videos]
▶ ETFs with exposure to Amarin Corp. Plc : June 2, 2017   [Jun-02-17 01:50PM  Capital Cube]
▶ 3 Healthcare Stocks for Savvy Investors   [May-24-17 03:46PM  Motley Fool]
▶ ETFs with exposure to Amarin Corp. Plc : May 22, 2017   [May-22-17 01:20PM  Capital Cube]
▶ ETFs with exposure to Amarin Corp. Plc : May 11, 2017   [May-11-17 04:06PM  Capital Cube]
▶ Amarin reports 1Q loss   [05:06AM  Associated Press]
▶ ETFs with exposure to Amarin Corp. Plc : April 26, 2017   [Apr-26-17 03:04PM  Capital Cube]
▶ ETFs with exposure to Amarin Corp. Plc : April 7, 2017   [Apr-07-17 03:46PM  Capital Cube]
▶ 3 Stocks That Could Make You Rich   [Mar-28-17 12:24PM  Motley Fool]
▶ 3 Stocks That Could Make You Rich   [12:24PM  at Motley Fool]
▶ 4 Biotech Stocks With Jaw-Dropping Growth Potential   [Mar-21-17 08:09AM  Motley Fool]
▶ Amarin reports 4Q loss   [06:21AM  Associated Press]
▶ 1 Reason Amarin's Stock Skyrocketed in 2016   [Jan-10-17 09:39AM  at Motley Fool]
▶ Is CytomX Therapeutics Inc (CTMX) A Good Stock To Buy?   [Dec-13-16 02:05PM  at Insider Monkey]
▶ Is Loxo Oncology Inc (LOXO) Worthy of Your Portfolio?   [Dec-11-16 08:46AM  at Insider Monkey]
▶ Is Modine Manufacturing Co. (MOD) A Good Stock To Buy?   [Dec-10-16 10:07AM  at Insider Monkey]
▶ Do Hedge Funds Love Amarin Corporation plc (ADR) (AMRN)?   [Dec-08-16 07:14AM  at Insider Monkey]
▶ Penny Stocks: 2 to Buy, 2 to Avoid   [Nov-20-16 07:26AM  at Motley Fool]
▶ Amarin's Stock Buckled in October. Is It Now a Bargain?   [Nov-09-16 08:52AM  at Motley Fool]
▶ 10 Analyst Stocks Under $10 With Massive Upside Projections   [Oct-23-16 09:05AM  at 24/7 Wall St.]
Stock chart of AMRN Financial statements of AMRN
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.